Engineered TCR targeting aberrant neoantigens NY-ESO1 (Lete-cel) and MAGE-A4 (Afami-cel) have shown ORR 40–60% in synovial sarcoma, with a favorable safety profile. The gene discussed is MAGEA4; the disease is synovial sarcoma.